| Grant Title | Grantor | Amount | Award Date |
|---|
| Carol Wallace, MD | CARRA- Accelerating Toward an Evidence Based Culture in Pediatric Rheumatology | NIH-NIAMS |
$09.01.09 | 47,930.00 |
| Shaun W. Jackson, MD | University of Washington Child Health Research Center (CHRC) | NIH |
$$85,000/year | July 1, 2012 - June 30, 2014 |
| Shaun W. Jackson, MD | ACR REF Rheumatology Scientist Development Award | American College of Rheumatology |
$$50,000-$75,000/year | July 1, 2012 - June 30, 2014 |
| Carol Wallace, MD | TREAT Follow-up Study | Amgen |
$338,125.00 | Nov. 7, 2009 |
| Carol Wallace, MD | Dynamics of Therapeutic Response within the TREAT trial | NIH-NIAMS |
$15,284.00 | Sept. 1, 2009 |
| Carol Wallace, MD | Trial of Early Aggressive Therapy of Juvenile Idiopathic Arthritis (TREAT) | NIH- NIAMS |
$193,417.00 | Sept. 1, 2009 |
| Carol Wallace, MD | Comparative Effectiveness Research in Pediatric Rheumatic Diseases: Leveraging CARRA for Improved Child Health | NIH-NIAMS |
$994,839.00 | Sept. 1, 2009 |
| Sarah Ringold, MD | Measuring Disease Activity in Juvenile Idiopathic Arthritis | American College of Rheumatology Research and Education Foundation Clinical Investigator Fellowship Award | | July 1, 2009 |
| Carol Wallace, MD | Dynamic Assessment in Multicenter Trials – Supplement to Expand Testing of Pediatrics PROMIS Tool | NIH |
$15,000.00 | May 1, 2009 |
| Carol Wallace, MD | STRIVE- Long term, multi-center, longitudinal post-marketing, observational registry of Humira in children with active Juvenile Idiopathic Arthritis. Per patient enrolled payments | Abbott |
$per patient enrollment | May 1, 2009 |
| Sarah Ringold, MD | Measuring Outcomes in Polyarticular Juvenile Idiopathic Arthritis | Seattle Children’s Hospital Center for Clinical and Translation Research, Mentored Scientist Program | | Aug. 1, 2008 |
| Carol Wallace, MD | Randomized Placebo Phase study of Rilonacept in the Treatment of systemic juvenile idiopathic arthritis | NIH-NIAMS |
$Per patient enrolled payments | July 1, 2008 |
| Anne Stevens, MD, PhD | Mechanisms of PD-L1 Dysregulation in Pediatric Lupus | Lupus Research Institute |
$300,000.00 | Nov. 1, 2007 |
| Carol Wallace, MD | CARRA Enhanced Drug Safety Surveillance Study | Pfizer |
$289,050.00 | Oct. 1, 2007 |
| Anne Stevens, MD, PhD | Maternal Microchimerism in Pediatric Systemic Lupus Erythematosus | Lupus Foundation of America |
$66,500.00 | Oct. 1, 2007 |
| Anne Stevens, MD, PhD | Maternal Microchimerism in Pediatric Systemic Lupus Erythematosus | Arthritis Foundation Investigator Award |
$180,000.00 | July 1, 2007 |
| Anne Stevens, MD, PhD | Pregnancy, Microchimerism, and Autoimmune Disease | NIH | | April 1, 2007 |
| Carol Wallace, MD | Early Aggressive Therapy in Juvenile Idiopathic Arthritis (TREAT) | NIH – NIAMS |
$4,136,107.00 | Sept. 1, 2006 |
| Carol Wallace, MD | Private donation - To support research in Juvenile Rheumatoid Arthritis proceeds from endowment | Private | | Jan. 1, 2004 |
| Anne Stevens, MD, PhD | Alloimmunity in autoimmune disease | NIH | | Aug. 1, 1999 |
| Carol Wallace, MD | National Collaborative Study of Stem Cell Transplantation | n/a |
$unfunded | May 1, 1999 |
| Anne Stevens, MD, PhD | Mechanisms of Tolerance to Renal Maternal Microchimerism | NIH |
$07.01.07 | 1,250,000.00 |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |